Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363376 · ClinicalTrials.gov registry record · Phase 3
A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
A Phase 3 study, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
NCT00363376: Completed Phase 3 study, sponsored by Lindner Center of HOPE.
NCT00363376 is a Phase 3 study that has completed, run by Lindner Center of HOPE. The registered enrollment target is 42 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00363376, a Phase 3 study, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
Study Summary
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of zonisamide therapy in the prevention of weight gain associated with olanzapine treatment for psychotic or bipolar disorders.
Interventions
- DRUG Zonisamide
- DRUG olanzapine
- DRUG Sugar Pill (placebo)
- DRUG zonisamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
What the finished NCT00363376 record still lists
NCT00363376 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Zonisamide is the first listed.
NCT00363376 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00363376 about?
NCT00363376 is a clinical study titled "A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain". The specific aim of this study is to evaluate the efficacy, tolerability, and safety of zonisamide therapy in the prevention of weight gain associated with olanzapine treatment for psychotic or bipolar disorders.
What is the current status of trial NCT00363376?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2008-01. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00363376?
The interventions under investigation include: Zonisamide (DRUG), olanzapine (DRUG), Sugar Pill (placebo) (DRUG), zonisamide (DRUG).
Who is sponsoring clinical trial NCT00363376?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00363376's enrollment target sits among peer trials
42 1877th of 2000 higher than 124 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia